Rapamycin (Sirolimus)

Licensed by Pfizer 製品コードS1039 別名:AY 22989,NSC-2260804

Rapamycin (Sirolimus)化学構造

分子量(MW):914.18

Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。

サイズ 価格(税別)  
JPY 50796.00
JPY 11620.00
JPY 44820.00
JPY 111220.00

文献中の使用例(63)

カスタマーフィードバック(12)

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

製品安全説明書

mTOR阻害剤の選択性比較

生物活性

製品説明 Rapamycin (Sirolimus)は一種の特定なmTOR 阻害剤で、HEK293細胞中でIC50 値が約0.1 nMです。
ターゲット
mTOR [1]
(HEK293 cells)
~0.1 nM
体外試験

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NFnOR2VEgXSxdH;4bYMhSXO|YYm= MlfCNVAhdk1? NXvHdVRtPzJiaB?= NVHUPVF6TE2VTx?= MX\Qc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= NUT3Nno{OjR7MEC4O|M>
HT-29 MXfDfZRwfG:6aXOgRZN{[Xl? NFOwNosyOCCwTR?= M3\2NVczKGh? NGG0WppFVVOR MXPQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? NGDaZ4YzPDlyMEi3Ny=>
HT-29 NGfhNFlEgXSxdH;4bYMhSXO|YYm= M1vOZlExKG6P NGnDeYg4OiCq MWnEUXNQ NVX3TJFYWG:2ZX70bYF1\XNiNT3mcJVwem:3cnHjbYwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NGrjT4MzPDlyMEi3Ny=>
PC3 MVXLbY5ie2ViQYPzZZk> M4PjdlExOCCwTR?= NXzt[|ZUOSCq M1;LUGROW09? NX\wUm5DWG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDxzMDDuUU4> MnPWNlE6Pzh4OEO=
PC3 M{jtSGtqdmG|ZTDBd5NigQ>? NGO5bXUyODBibl2= NV\UfYhCOSCq MVPEUXNQ MUHEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M1\PdFIyQTd6Nkiz
PC3 M{LQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPmbpEyNjVizszN MWCxJIg> M1jyWWROW09? MmXHTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P Mlq5NlE6Pzh4OEO=
HEK293 MYnGeY5kfGmxbjDBd5NigQ>? MVmxNFAhdk1? MYG4JIg> M13PdWROW09? M1y0PWlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?= MUSyNVU{QTNyMR?=
BT-20 M4O4fmtqdmG|ZTDBd5NigQ>? M3z1R|IxKM7:TR?= M1uyVWROW09? MXXEc4V{KG6xdDDpcohq[mm2IH3UU3JEOiCmZYDlcoRmdnRicFHrWEBUPDd|IIDoc5NxcG:{eXzheIlwdg>? M3TCelIyOzV|NUWx
U937 MXLBcpRq[mGldHXybYFtKEG|c3H5 NFn4cFA2OCEQvF2= MUO0PEBp NXrLd|JLTE2VTx?= M3jxSmlv\HWlZYOgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KHerbHSgeJlx\SCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJHBpcWyjZHXsdIhq[S1zIFrSN|IhcW5iVUmzO{Bk\Wyucx?= M1\GTFIyOTR{MUC2
U937 M1nOO2FvfGmkYXP0[ZJq[WxiQYPzZZk> MYK1NEDPxE1? MVi0PEBp NF7vUGxFVVOR NHzKUVVFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy| M3fGbVIyOTR{MUC2
U937 NV;BXlYySW62aXLhZ5RmemmjbDDBd5NigQ>? NFf5OG42OCEQvF2= NX3ud4tZPDhiaB?= NUH4[m1MTE2VTx?= NWTZ[lhzTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCHc3Po[ZJq[2irYTDjc4xqKEiEMUCxJIlvKFV7M{egZ4VtdHN? MkfGNlEyPDJzME[=
MCF-7 MmH2RZV1d3CqYXf5JGF{e2G7 M1n5dFMxKG6P NFnjOXc1KGh? NFHLO3dFVVOR Mn\ZTY5lfWOnczDheZRweGijZ4m= NX7oV4V4OjByMkixN|Q>
U87MG M3r3fmtqdmG|ZTDBd5NigQ>? Moe2NUDPxE1? M1WxdFYhcA>? NWDnWlNMTE2VTx?= M2XjdHBwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w Mn;PNVk5PDh2MES=
U87MG NHLKPGpMcW6jc3WgRZN{[Xl? MnrXNUDPxE1? Mln5OkBp NX:w[mU1TE2VTx?= MUTQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= NXfZPY9SOTl6NEi0NFQ>
U87MG MYHLbY5ie2ViQYPzZZk> MWixJO69VQ>? NIjKVlc3KGh? M2HBbWROW09? MlLmSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MXSxPVg1QDRyNB?=
U87MG NXLiOnhtU2mwYYPlJGF{e2G7 M3y1SFEh|ryP Mn;6OkBp NIHXWWpFVVOR M3fIUmRw\XNibn;0JIlvcGmkaYSgVE01TUKSMTjUN|cwPDZrIIDoc5NxcG:{eXzheIlwdg>? MlPxNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rheb NWPSOVBRSXW2b4DoZYd6KEG|c3H5 NUDoUXg4OC5{IN88US=> Mkn1NlQhcA>? MX7EUXNQ MV\JcoR2[2W|IHH1eI9xcGGpeR?= Mkj0NVg{QTF7NEm=
COS7 cells expressing EGFP-LC3 MlTVRZV1d3CqYXf5JGF{e2G7 M1TzUlAvOiEQvF2= NHHJSVYzPCCq NFfqfIZFVVOR M1GweGlv\HWlZYOgZZV1d3CqYXf5 MlnCNVg{QTF7NEm=
H4 NX\lZW5XTnWwY4Tpc44hSXO|YYm= NGi0eVkxNjJizszN MXKyOEBp MkDQSG1UVw>? NWfmcJM1UW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? M3fhVlE5ODJ2NUi0
HeLa MkHMSpVv[3Srb36gRZN{[Xl? MVSxNFAhdk1? MYGzOkBp MVrEUXNQ NVPJd5pZUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NVzKWpVwOTd3NkOzPFU>
HeLa M2DVWWZ2dmO2aX;uJGF{e2G7 MUixNFAhdk1? NVruZ|h[OzZiaB?= NH;qdGhFVVOR NVu1RWtDUW6mdXPld{BHWkJiV{KxNFFHKG23dHHueE12[mmzdXn0bY5EKGmwdHXyZYN1cW:w MYGxO|U3OzN6NR?=
HeLa NXOxTZduTnWwY4Tpc44hSXO|YYm= NFu4cZMyODBibl2= MnjJN|YhcA>? M124TWROW09? MnH2TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u MYmxO|U3OzN6NR?=
SYF NWrsNol1TnWwY4Tpc44hSXO|YYm= M3qydFExOCCwTR?= MVGyOEBp NGHqSmxFVVOR MUTJcoR2[2W|IF\SRk1HU0KSIHPvcZBt\XhiaX70[ZJi[3Srb36= M{DHUFE4PTZ|M{i1
SYF MkfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLHNVAxKG6P M2jhbVI1KGh? NFXPVWpFVVOR NWfOcY46UW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> MV6xO|U3OzN6NR?=
HEK293T NYi3SmUySW62aY\pdoFtKEG|c3H5 M4nUOlEhdk1? MX[0JIQ> MXnEUXNQ MoDMTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFJ3IIfpeIghTUN3MDDv[kAxNjFibl2= M1;ETFE4PDh3NUCx
HEK293T M4PnSWFvfGm4aYLhcEBCe3OjeR?= M1\GT|Ehdk1? M33GNFQh\A>? MU\EUXNQ MUHJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?= NXHj[pVoOTd2OEW1NFE>
PBMC MmTTSpVv[3Srb36gRZN{[Xl? M1rR[VEhdk1? MXKxOEBl NWTkS5VOTE2VTx?= NX\GbYF{WmWmdXPld{BES1J3IHTlcpNqfHl? MWixO|Q5PTVyMR?=
PBMC NF3mb25HfW6ldHnvckBCe3OjeR?= NE\FZnkyKG6P NX74cnJbOTRiZB?= MVrEUXNQ MkniSI9meyCwb4SgZYZn\WO2IFPYR3I1KGSnboPpeJk> NWqwOJVJOTd2OEW1NFE>
HEK293 cells M1\0cGtqdmG|ZTDBd5NigQ>? M{XzZVUxKG6P NFTLbVU1PSCvaX6= NW\1clQzTE2VTx?= MmPpTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? NWPIeJl2OTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc NGDJb4VHfW6ldHnvckBCe3OjeR?= NIfUfZcyODBibl2= NGq4OXQ1KGh? MkTMSG1UVw>? M3Gzemlv\HWlZYOgcJVkcW[ncnHz[UBxem:2ZXnuJJRz[W6|LYPwcIlkcW6pIHnuJGRzd3OxcHjpcIEhdWWuYX7v[4F{fGW{IGOyJINmdGy|IITyZY5{\mWldHXkJJdqfGhiTj3seYMh[W6mIFOtcJVk M13lSFE4OTJ6Mk[y
Human mixed lymphocyte MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3OVUhdk1? MlvXSG1UVw>? M{GzZmlEPTB;MT62JI5ONg>? MWSxOlE5PTh4NR?=
Lewis rat lymph node cells NHq0W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVm1JO69VQ>? MUnEUXNQ NVHrdGJUUUN3ME2yMlYh|ryP M1PySFE3OTh3OE[1
cells from the thymus of normal BALB/c mice M4[1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDHNVAhdk1? NF7ld4E4OiCq MUDEUXNQ M1y1TGlvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= M{PMRlExODJzOUS4
MRK-nu-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TQbGlEPTB;MD64OFUheE1? Mk[xV2FPT0WU
OCUB-M NXnGPFkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwMkSgdG0> MUfTRW5ITVJ?
SF539 MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DRS2lEPTB;MUGuOkBxVQ>? MmrsV2FPT0WU
ES4 NVvFTZE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HNT2lEPTB;MkGuOUBxVQ>? MXLTRW5ITVJ?
RL95-2 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjwOppKSzVyPUGwO{BxVQ>? NV7Od2xmW0GQR1XS
LC-2-ad Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XFTWlEPTB;NEKzJJBO MmrpV2FPT0WU
Daudi MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu4TZlKSzVyPUSzOEBxVQ>? MoDZV2FPT0WU
NTERA-S-cl-D1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle5TWM2OD12NEOgdG0> NHfD[pRUSU6JRWK=
OS-RC-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLuOmVxUUN3ME22OVIheE1? Mme3V2FPT0WU
VA-ES-BJ Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr0[WVHUUN3ME23NlMheE1? NEDRbmtUSU6JRWK=
GR-ST MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXDPGNmUUN3ME24OFYheE1? NHTXN25USU6JRWK=
SW872 M4LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD16NE[gdG0> NEPibYxUSU6JRWK=
NOS-1 NHS1PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HHNGlEPTB;OEexJJBO MlPFV2FPT0WU
MC116 NGfWNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfPWINKSzVyPUm4OUBxVQ>? NIrKc4FUSU6JRWK=
NCI-H1355 NFrjb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;lNmlEPTB;MT6wNUBvVQ>? NHvGW3lUSU6JRWK=
RPMI-8226 NXraXpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\GWWlEPTB;MT6xPUBvVQ>? M1TFPXNCVkeHUh?=
TE-15 NYXhWXk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{[gcm0> NHrmbJBUSU6JRWK=
Ramos-2G6-4C10 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVja[mpCUUN3ME2xMlQ3KG6P NEPwSZlUSU6JRWK=
KU812 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzkTWM2OD1{LkCxJI5O MkHPV2FPT0WU
EW-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K1cWlEPTB;Mj6xO{BvVQ>? MXTTRW5ITVJ?
KS-1 NV\pTFRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFTWM2OD1{LkS1JI5O MYTTRW5ITVJ?
SK-LMS-1 NF3EPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPWelJKSzVyPUKuOFkhdk1? MoH3V2FPT0WU
TGBC1TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFmyWoRKSzVyPUKuOlkhdk1? NWnNXFZqW0GQR1XS
TE-6 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPkTWM2OD1{Lke3JI5O MorPV2FPT0WU
ETK-1 M2q5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi4O2dPUUN3ME2yMlgzKG6P MYfTRW5ITVJ?
BE-13 NWHSSXpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOOZFiUUN3ME2yMlk6KG6P M{j5ZnNCVkeHUh?=
A3-KAW Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y2RmlEPTB;Mj65PUBvVQ>? NWj4d3lKW0GQR1XS
TE-10 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf0OFVKSzVyPUOuN{BvVQ>? MkjIV2FPT0WU
DOHH-2 NVTaUGtJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF20ZpZKSzVyPUOuN|Uhdk1? NUT3TGxxW0GQR1XS
ES6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTNwNEOgcm0> NYHRXI5ZW0GQR1XS
OPM-2 M3H2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF2zSWlKSzVyPUSuNVUhdk1? MYjTRW5ITVJ?
SH-4 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwM{Sgcm0> MVXTRW5ITVJ?
NB13 NInydoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH4TWM2OD12LkO2JI5O MVTTRW5ITVJ?
HUTU-80 NWHnSo43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;XbGF5UUN3ME20MlQzKG6P MnThV2FPT0WU
CCRF-CEM MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ScnZUUUN3ME20Mlk1KG6P NUXieHdoW0GQR1XS
TGBC24TKB M3nBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIqwN5BKSzVyPUWuOVEhdk1? Mn\FV2FPT0WU
697 NVLNbVI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTZwMkigcm0> NGnEdpJUSU6JRWK=
J-RT3-T3-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXETWM2OD14LkS2JI5O NV\oV2g5W0GQR1XS
KALS-1 NVK3VZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnSWFg4UUN3ME22MlU3KG6P MlnqV2FPT0WU
no-10 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W4e2lEPTB;Nz6yPUBvVQ>? MX3TRW5ITVJ?
SK-NEP-1 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1KzSGlEPTB;OD63PUBvVQ>? MnXUV2FPT0WU
L-540 M4[wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj4WGFwUUN3ME2xNE41OiCwTR?= NXrtWGo5W0GQR1XS
JiyoyeP-2003 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjSTWM2OD1zMD65OEBvVQ>? NFTrNZlUSU6JRWK=
HH M1m1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknMTWM2OD1zMT6zPUBvVQ>? NUDOOYZYW0GQR1XS
SR M3\YWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPM[oFKSzVyPUGxMlQ2KG6P NY\SSHVnW0GQR1XS
QIMR-WIL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS3TWM2OD1zMT64OUBvVQ>? MW\TRW5ITVJ?
A4-Fuk NV3IW4U4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rxSWlEPTB;MUOuNVIhdk1? NIrObZlUSU6JRWK=
CESS NGDIfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\SRmRKSzVyPUGzMlE{KG6P MoLZV2FPT0WU
KE-37 M2P1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF4LkC3JI5O NYqz[Ww2W0GQR1XS
SK-UT-1 MnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W2cmlEPTB;MU[uPFEhdk1? NXz1[YF2W0GQR1XS
SIG-M5 NVSy[nBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYNmlEPTB;MUeuNlUhdk1? NU\uVYU2W0GQR1XS
HT MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnETWM2OD1zNz62JI5O MYjTRW5ITVJ?
DEL MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHRTWM2OD1zNz65PUBvVQ>? M1:2bXNCVkeHUh?=
SK-PN-DW NWflUZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37tVGlEPTB;MkCuNlMhdk1? MnzEV2FPT0WU
RPMI-8402 M3PQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJzLke3JI5O Mn:yV2FPT0WU
RPMI-6666 NFflfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvsTWM2OD1{ND60NkBvVQ>? NVXSdIxwW0GQR1XS
NCI-H720 NH[4TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjWXlVoUUN3ME2yOU41OSCwTR?= MlvKV2FPT0WU
EW-16 M4L6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHKTWM2OD1{Nj64O{BvVQ>? M3fKTXNCVkeHUh?=
BL-70 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq1S|BKSzVyPUK4MlM5KG6P MYrTRW5ITVJ?
SF126 M4fHZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HlSGlEPTB;M{CuN|ghdk1? M2roe3NCVkeHUh?=
BC-1 NUniU|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L6O2lEPTB;M{GuNlYhdk1? NH7GSGdUSU6JRWK=
MHH-PREB-1 NXnMdmpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G0dmlEPTB;M{KuOFQhdk1? MlL3V2FPT0WU
A101D MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELTVZdKSzVyPUOyMlYzKG6P MmnYV2FPT0WU
NMC-G1 NIjuRXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3tTGEzUUN3ME2zN{43PyCwTR?= M3jOWXNCVkeHUh?=
LB1047-RCC M4i3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfae4xKSzVyPUO0MlY6KG6P MYLTRW5ITVJ?
EM-2 NG[xeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\WeWlEPTB;M{iuOVMhdk1? NHnGT41USU6JRWK=
COLO-684 NHHSdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLoTWM2OD1|OT64JI5O NX7KUow{W0GQR1XS
Becker MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rzc2lEPTB;NEGuNFUhdk1? NYTUbpcxW0GQR1XS
BL-41 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjS2lEPTB;NEOuOlYhdk1? NXK1U5FoW0GQR1XS
MDA-MB-134-VI NEO5VWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7jbm5UUUN3ME20OE4xOiCwTR?= MkG3V2FPT0WU
L-363 NUPBc|YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvZXXhqUUN3ME20OE44OyCwTR?= M3rXWXNCVkeHUh?=
ECC4 NIPlU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTR2Lke4JI5O M{LsOHNCVkeHUh?=
A388 MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXeyXnBzUUN3ME20OE45OiCwTR?= NFq3WVNUSU6JRWK=
HEL MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTR7Lke5JI5O MXXTRW5ITVJ?
RKO NF70e2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITZS4hKSzVyPUWwMlI6KG6P MXXTRW5ITVJ?
KINGS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTVzLkW1JI5O M3uz[nNCVkeHUh?=
EB-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXHTWM2OD13Mj62O{BvVQ>? NYnTTllXW0GQR1XS
ARH-77 M4DPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LLUWlEPTB;NUKuPEBvVQ>? NUfz[2NmW0GQR1XS
GCIY MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPZTWM2OD13Mz60OkBvVQ>? MmfrV2FPT0WU
NCI-H1304 M1OxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPa[2xtUUN3ME21O{4zOiCwTR?= NHzqVXNUSU6JRWK=
KARPAS-299 M{\wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjkWY04UUN3ME22NU45OiCwTR?= MmHVV2FPT0WU
IA-LM MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZ6LkGzJI5O NWDR[3lVW0GQR1XS
GI-1 NXexdlUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrkSGtKSzVyPUewMlM6KG6P NGTTdZRUSU6JRWK=
TE-11 M3y5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDUOpRKSzVyPUe3MlE4KG6P NFXQ[WpUSU6JRWK=
LS-411N NEXCSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\LNGZKSzVyPUe3MlU4KG6P MWPTRW5ITVJ?
no-11 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DjXmlEPTB;OEOuNlQhdk1? MWXTRW5ITVJ?
MV-4-11 M{LyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zzNWlEPTB;OEOuO|Mhdk1? NH3uW|hUSU6JRWK=
BV-173 M1;temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTh|Lkm3JI5O NHjUZ4JUSU6JRWK=
CMK NWXRXHc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrMeGFNUUN3ME24OE4yPiCwTR?= M2KxfHNCVkeHUh?=
LC4-1 NF7QO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTh4LkeyJI5O NEXWc|lUSU6JRWK=
COR-L279 NVSxPFVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLCdYRKSzVyPUi3MlI2KG6P NGrwcVJUSU6JRWK=
NCI-H209 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTB[FZKSzVyPUi3MlQyKG6P MlnYV2FPT0WU
Raji NX21V5pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;TTWM2OD16OT63NkBvVQ>? M3vGc3NCVkeHUh?=
LB996-RCC MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TsR2lEPTB;OUOuOFMhdk1? NV7iXIJnW0GQR1XS
NCI-H526 NYS2W2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW3TWM2OD17Mz61PUBvVQ>? Mk\LV2FPT0WU
KGN MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXENVhoUUN3ME25Ok4zQSCwTR?= NXf5N2FlW0GQR1XS
MOLT-4 NGLsSm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj1WIlKSzVyPUm2Mlc6KG6P MXTTRW5ITVJ?
PF-382 NHvUe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf0Xo1WUUN3ME25Ok44QSCwTR?= MlP6V2FPT0WU
BC-3 M33JOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTl7LkG4JI5O NWm4U3FrW0GQR1XS
KARPAS-422 NHXtUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGzVY9WUUN3ME2xNFIvODlibl2= NHvFelRUSU6JRWK=
SBC-1 NVrmPGViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyxeZZKSzVyPUGwO{44PSCwTR?= Ml\jV2FPT0WU
LC-1F M1;LRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xv[2lEPTB;MUC4MlA2KG6P NFjWbIhUSU6JRWK=
GB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C3PWlEPTB;MUC5MlAzKG6P Mn;tV2FPT0WU
SNB75 NHP6dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n2UWlEPTB;MUG5MlY6KG6P NVzSbJNjW0GQR1XS
BB65-RCC NGPFU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jqcWlEPTB;MUG5Mlk{KG6P Mn73V2FPT0WU
NCI-N87 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHwTHpKSzVyPUGyNU46QCCwTR?= M{jTNnNCVkeHUh?=
IST-MEL1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj2[5ZKSzVyPUGyNk4{QCCwTR?= MUfTRW5ITVJ?
HOP-62 M1u2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n3d2lEPTB;MUK2Mlg6KG6P MoPXV2FPT0WU
ACN NF24bnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TLS2lEPTB;MUS2Mlc2KG6P MnjYV2FPT0WU
DMS-114 NXS0R3JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfsTWM2OD1zNUCuOlchdk1? NInMWlhUSU6JRWK=
MLMA M2fTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTF3OT64PEBvVQ>? M3m1N3NCVkeHUh?=
HT-144 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPtTWM2OD1zNkWuOFMhdk1? MXLTRW5ITVJ?
C2BBe1 NInPelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXI[lA2UUN3ME2xOlcvPzZibl2= MVPTRW5ITVJ?
L-428 NH;5SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF5Nz63JI5O NWHSTWlLW0GQR1XS
DU-4475 M2fKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfkTWM2OD1zOEeuOlghdk1? MWnTRW5ITVJ?
CP67-MEL MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF7OT6zPEBvVQ>? M1HSb3NCVkeHUh?=
MEG-01 NY\F[4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PkZWlEPTB;MkCxMlk3KG6P NIryN|BUSU6JRWK=
IST-SL2 NGD6eY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJyOD62N{BvVQ>? NH\vT|VUSU6JRWK=
ES8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HpVWlEPTB;MkK1Mlk1KG6P NVm4VXdZW0GQR1XS
COLO-800 NVX0TVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPpfohKSzVyPUKzOU4zQCCwTR?= NYWxWJFrW0GQR1XS
MFH-ino NWfDfW46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjv[21KSzVyPUKzOU45PCCwTR?= Mke1V2FPT0WU
OVCAR-4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;kUVJzUUN3ME2yN|cvOjRibl2= NVjy[ZlwW0GQR1XS
PSN1 M3TtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH1TWM2OD1{NEKuO|Ehdk1? NVzndY1UW0GQR1XS
EW-12 M3zzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTSUmJKSzVyPUK0N{4yKG6P MXrTRW5ITVJ?
HCC1599 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkfHdKSzVyPUK2NU41PyCwTR?= NHnhZo5USU6JRWK=
SJSA-1 NILrVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrBUlVEUUN3ME2yO|EvPDZibl2= NFfHdXJUSU6JRWK=
ST486 M3fVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH:1XlNKSzVyPUK5Ok4yPCCwTR?= M3S0VXNCVkeHUh?=
NOMO-1 NUPVNnRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPPTWM2OD1|MECuNlEhdk1? Mk\uV2FPT0WU
MN-60 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fFWmlEPTB;M{C1MlMzKG6P MWHTRW5ITVJ?
HCC1187 NF\CSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NOVRRUUN3ME2zNFcvOjVibl2= MYfTRW5ITVJ?
SW982 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv0XGRFUUN3ME2zNVQvPzVibl2= NXfGfoZ5W0GQR1XS
LB647-SCLC NUDnXXFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHpcHJKSzVyPUOyPE44OSCwTR?= MkPyV2FPT0WU
HC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojOTWM2OD1|M{WuOUBvVQ>? NED1OYJUSU6JRWK=
EHEB NWPITJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[0TWM2OD1|M{euOVIhdk1? MX7TRW5ITVJ?
TUR MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzleYhKSzVyPUO2N{46PSCwTR?= NFjXWlFUSU6JRWK=
LU-139 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rmeWlEPTB;M{e4MlAzKG6P MWHTRW5ITVJ?
NB1 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTpb|JKSzVyPUO4OE41PSCwTR?= NHnMe5hUSU6JRWK=
BB30-HNC NVHUPFdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fseGlEPTB;M{i4MlMzKG6P NETvUINUSU6JRWK=
HAL-01 MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnk[XNKSzVyPUO4PU4zPiCwTR?= MoLkV2FPT0WU
K5 M{PCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PMWGlEPTB;NEGxMlM4KG6P M1rsTnNCVkeHUh?=
MZ2-MEL NGHGXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vEbGlEPTB;NEGzMlY1KG6P NEjlXGlUSU6JRWK=
RXF393 M2ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FS3ZHUUN3ME20NVYvPDVibl2= NUPXZYdUW0GQR1XS
NCI-H1648 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vpZ2lEPTB;NEG3MlU{KG6P MlPtV2FPT0WU
TE-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXYfFFNUUN3ME20N|QvOjZibl2= MofJV2FPT0WU
EoL-1- MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTR|Nz65PEBvVQ>? NFO5PZBUSU6JRWK=
JAR M33WWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;MSJRKSzVyPUSzPE43OiCwTR?= MlzJV2FPT0WU
DSH1 MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR3OD65NUBvVQ>? MV;TRW5ITVJ?
NCI-H187 NUTVOVdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[5ZWlEPTB;NE[yMlgyKG6P MX7TRW5ITVJ?
HCE-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfaNlBKSzVyPUS3O{43PiCwTR?= MXLTRW5ITVJ?
8-MG-BA NY\ybVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXFTWM2OD13OEGuOVIhdk1? NGDMXY9USU6JRWK=
KLE MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTV6NT6yJI5O NFezRYtUSU6JRWK=
KNS-42 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXCO5ZFUUN3ME21PFYvQDFibl2= NHr0[W5USU6JRWK=
MSTO-211H NH7rNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\ETWM2OD14MEmuO|Qhdk1? MYHTRW5ITVJ?
GDM-1 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\YTWM2OD14MUSuNFkhdk1? M4P0ZXNCVkeHUh?=
TE-1 NV31fZVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvlNm9KSzVyPU[0Ok4yOiCwTR?= Mnf6V2FPT0WU
BT-474 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYcmlEPTB;NkS3MlA3KG6P NUDOZoQ{W0GQR1XS
KARPAS-45 MonVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnIVZJFUUN3ME22OFcvPiCwTR?= MkjwV2FPT0WU
MOLT-16 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7CTWM2OD14NEeuPVMhdk1? M2DCTnNCVkeHUh?=
KURAMOCHI MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjqTWM2OD14NUeuOVEhdk1? NVi0RVFUW0GQR1XS
K-562 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK4OWtPUUN3ME22OlkvPTFibl2= MmD6V2FPT0WU
EKVX MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjuephkUUN3ME22O|IvPzFibl2= MkDHV2FPT0WU
GAK MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjKO5dKSzVyPU[3OU4{KG6P NUfDV3NsW0GQR1XS
NCI-SNU-5 NXLTelRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiwTWM2OD14OUCuNFEhdk1? NISwSGtUSU6JRWK=
NCI-H2126 NGTuc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zHeWlEPTB;N{K2Mlg4KG6P MlL1V2FPT0WU
CTV-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0SWlEPTB;N{S0Mlkhdk1? M2Xl[XNCVkeHUh?=
SW962 M12yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTd2OD60OEBvVQ>? NEPtO2RUSU6JRWK=
MONO-MAC-6 M3:5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f1PGlEPTB;N{W2Mlk{KG6P M3z2PXNCVkeHUh?=
NCI-H748 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XxW2lEPTB;N{W4Mlk6KG6P MUjTRW5ITVJ?
NCI-H524 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmyTWM2OD15OECuO|Mhdk1? NHnaW|NUSU6JRWK=
LS-123 NIjWRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTd7NT62PUBvVQ>? NX[1NWJQW0GQR1XS
NB7 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPlSJNKSzVyPUixOE4yPCCwTR?= NFnYS5NUSU6JRWK=
LS-1034 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTh{OD65PEBvVQ>? NHjIcXFUSU6JRWK=
TE-5 M{jGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jrW2lEPTB;OEizMlU3KG6P M3O5Z3NCVkeHUh?=
A704 M{LzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPNTWM2OD16OUmuNVUhdk1? MX;TRW5ITVJ?
TK10 NVz2SWg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTlzNj6wN{BvVQ>? M3ztU3NCVkeHUh?=
NCI-H345 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzeI1EUUN3ME25OFMvOjJibl2= NULTdYVsW0GQR1XS
CGTH-W-1 M1HRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTl2OD6xN{BvVQ>? M3:2W3NCVkeHUh?=
NCI-H510A MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULXb21sUUN3ME25PFUvOTJibl2= M2LINnNCVkeHUh?=
NCI-H1963 NYrmbYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\Md4s5UUN3ME2xMlA{Ojl{IN88US=> Mor1V2FPT0WU
SCC-3 NFjrboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXTbpJmUUN3ME2xMlA{PDF2IN88US=> NUXwV2tjW0GQR1XS
EW-11 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rTemlEPTB;MT6wPFc1OyEQvF2= MXTTRW5ITVJ?
CPC-N Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqwUHNjUUN3ME2xMlA5QCEQvF2= Mn;lV2FPT0WU
NCI-H1417 MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LQWGlEPTB;MT6xNlI3KM7:TR?= M2Txb3NCVkeHUh?=
DG-75 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMU[yPFUh|ryP MYjTRW5ITVJ?
HD-MY-Z M4S1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHruR4tKSzVyPUGuNVY1OTZizszN MknqV2FPT0WU
ATN-1 NU\6cZplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;TTWM2OD1zLkK2NlA6KM7:TR?= MnTxV2FPT0WU
KM-H2 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMk[0NFgh|ryP NI\oenlUSU6JRWK=
NCI-H2081 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMk[2N|ch|ryP MlP4V2FPT0WU
HL-60 NYnGN|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne5TWM2OD1zLkK2PVU6KM7:TR?= NYfkfnhTW0GQR1XS
DB NFPWdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwMkeyOFIh|ryP NEK0TnFUSU6JRWK=
NCI-H1522 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwMki4PFch|ryP M4nt[HNCVkeHUh?=
AM-38 NYi3[oE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjTU4FzUUN3ME2xMlMxPzJizszN NFTCO4VUSU6JRWK=
NCI-H446 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDqOJpKSzVyPUGuN|IyOjFizszN MkHlV2FPT0WU
SU-DHL-1 MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXhOGdCUUN3ME2xMlMzQDBzIN88US=> MmrCV2FPT0WU
NH-12 NIfQRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13nO2lEPTB;MT6zOlM4PCEQvF2= M2DPNHNCVkeHUh?=
DMS-79 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjtRoVCUUN3ME2xMlM3QDZ4IN88US=> M2\BdXNCVkeHUh?=
NCI-H716 NFrBb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkUmlEPTB;MT6zPFk5PiEQvF2= NH\MZW5USU6JRWK=
ML-2 NWPQNlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwNEG1Nlkh|ryP NHzzW|VUSU6JRWK=
NB10 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILvbFFKSzVyPUGuOFY3OzJizszN MoC3V2FPT0WU
ONS-76 NGX3UY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD2TWM2OD1zLkWzOVY6KM7:TR?= NEH5TpBUSU6JRWK=
LOUCY NFPtfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHiS5pSUUN3ME2xMlU1PjV5IN88US=> NYX4cZFSW0GQR1XS
SCLC-21H Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LqdWlEPTB;MT61PFU5OiEQvF2= MnjiV2FPT0WU
TGW NFP2e5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XMVmlEPTB;MT62N|k4PSEQvF2= NFvqXFhUSU6JRWK=
LXF-289 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD1zLkezNlY5KM7:TR?= MXnTRW5ITVJ?
BB49-HNC MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf5WJVKSzVyPUGuO|M2QDZizszN MlrVV2FPT0WU
NCI-H747 NHrUVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7k[JBKSzVyPUGuO|U{PDZizszN MlnkV2FPT0WU
LU-165 NVGwPG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwOES5PFYh|ryP MUfTRW5ITVJ?
OMC-1 NEDJXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3FV|NKSzVyPUGuPVUxPjZizszN M{nWXHNCVkeHUh?=
RCC10RGB M2WzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrJTWM2OD1zLkm1PFE4KM7:TR?= M3HsbHNCVkeHUh?=
SW684 M37RN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP5TWM2OD1zLkm2NFk6KM7:TR?= M4qzOXNCVkeHUh?=
TE-8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknITWM2OD1{LkC1OVU6KM7:TR?= M4G0eHNCVkeHUh?=
SK-N-DZ M4XhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnjRZRKSzVyPUKuNVMzPzRizszN M3zwUXNCVkeHUh?=
EVSA-T NHu4dotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DsWGlEPTB;Mj6xO|MyPSEQvF2= MWnTRW5ITVJ?
KASUMI-1 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LVdGlEPTB;Mj6xPFgyPSEQvF2= MkD1V2FPT0WU
NKM-1 M3vremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPCcXhKSzVyPUKuNlU1PzJizszN M3u4[HNCVkeHUh?=
CAL-148 Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwM{O2NVQh|ryP MV;TRW5ITVJ?
NCI-H64 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M16zR2lEPTB;Mj6zOFI{OiEQvF2= MVnTRW5ITVJ?
KNS-81-FD M4HWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ThOWlEPTB;Mj6zOlYzKM7:TR?= M{jGXHNCVkeHUh?=
KM12 M2Wxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ThVWlEPTB;Mj60NFg{QSEQvF2= NVzHRmpkW0GQR1XS
SW954 NGP4fYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDmc21VUUN3ME2yMlQ4Pzd7IN88US=> NW\0[YNIW0GQR1XS
NCI-H1395 NH2zeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwNUK2OFUh|ryP NWHZcHdlW0GQR1XS
DJM-1 M2D5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwNkC2N{DPxE1? M{HyNXNCVkeHUh?=
COLO-668 NGW0cmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDM[Vd6UUN3ME2yMlgzPjl3IN88US=> NFTLWYVUSU6JRWK=
NCI-H1436 MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXKTWM2OD1{Lki1OlE2KM7:TR?= MXTTRW5ITVJ?
LB2241-RCC NWfVe4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\RVYxKSzVyPUKuPFY5OzlizszN M2T1fXNCVkeHUh?=
GT3TKB NV3xdJd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwOEmwOVUh|ryP M2q4NnNCVkeHUh?=
COLO-824 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7JeWZKSzVyPUKuPFk4PjhizszN MlrFV2FPT0WU
ES1 NUfiWW9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLYTWM2OD1{Lki5PFc6KM7:TR?= MmfMV2FPT0WU
LB771-HNC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJwOUC5OFYh|ryP MnPHV2FPT0WU
GI-ME-N MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTNwMEC5NFQh|ryP M3rzNHNCVkeHUh?=
NALM-6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2cmlnUUN3ME2zMlAxQTN|IN88US=> M3PTVXNCVkeHUh?=
LU-134-A MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kTWM2OD1|LkC1OFI2KM7:TR?= MUjTRW5ITVJ?
DMS-153 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMemlEPTB;Mz6wOVgzPCEQvF2= NW[2TJpFW0GQR1XS
MZ1-PC M2TIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TOS2lEPTB;Mz6wPVA4QCEQvF2= NVfFWGd4W0GQR1XS
NCI-H1155 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNwMUG2NUDPxE1? MUDTRW5ITVJ?
CAS-1 NVq0[4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNwMUO3NFch|ryP M13BbHNCVkeHUh?=
D-502MG NH\0dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwMUSzPUDPxE1? NGHRd3lUSU6JRWK=
NCI-H2141 M1POUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzOeHlZUUN3ME2zMlE4PDV{IN88US=> NFjQ[ZRUSU6JRWK=
NB6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TVdGlEPTB;Mz6xPFI2QSEQvF2= MW\TRW5ITVJ?
NCCIT MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIO5N|ZKSzVyPUOuNlE5ODlizszN M3r0WHNCVkeHUh?=
NB69 NVXo[INQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD1|LkOxPFkyKM7:TR?= NGjNeoRUSU6JRWK=
JVM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTNwM{[0N|Mh|ryP Ml7FV2FPT0WU
K052 M2OxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPTTWM2OD1|LkO3PVY5KM7:TR?= NFLxdoNUSU6JRWK=
HCC2157 NHi5XGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNUOyNlgh|ryP MXvTRW5ITVJ?
KMOE-2 M1L0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG3fWhoUUN3ME2zMlU1OjR{IN88US=> NVjmNWNKW0GQR1XS
SF268 NU\QW|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXWb5RSUUN3ME2zMlcyPTV2IN88US=> M2T5[HNCVkeHUh?=
CHP-126 NITncHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS0TWM2OD1|Lke2OFU5KM7:TR?= NXHWWmpOW0GQR1XS
CP66-MEL NWXYNnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUmzOWgzUUN3ME2zMlc6ODl2IN88US=> M{fNcHNCVkeHUh?=
NCI-H69 M{\kV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXQNJJKSzVyPUSuNFE6OzZizszN M4X0O3NCVkeHUh?=
A253 M3jqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHae3ZtUUN3ME20MlAzOTBzIN88US=> NVrPR4piW0GQR1XS
NB14 M3LlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTRwMUC0O|kh|ryP MlS0V2FPT0WU
NCI-H1694 NHjRNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr2TWM2OD12LkGzNVEzKM7:TR?= MUHTRW5ITVJ?
NCI-H2196 NYDoR4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqPYxKSzVyPUSuNVcyPjlizszN M{XiUnNCVkeHUh?=
TE-9 Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W1PWlEPTB;ND6xO|U5OiEQvF2= M17iVHNCVkeHUh?=
D-283MED Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vSeWlEPTB;ND6xPFg1KM7:TR?= NYLSR4cxW0GQR1XS
OCI-AML2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzaZpVXUUN3ME20MlE6PDh7IN88US=> NXLwfIh3W0GQR1XS
D-263MG M{i5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzWWlFtUUN3ME20MlIzQTZzIN88US=> NIjydJhUSU6JRWK=
MPP-89 NVHCbW1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ewd2lEPTB;ND6yO|MxPCEQvF2= Mnr0V2FPT0WU
LAMA-84 NYLjR2I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnKTWM2OD12LkOwOFIyKM7:TR?= NHfUdmJUSU6JRWK=
LB373-MEL-D M4HidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHQS2FKSzVyPUSuN|Y4QDlizszN MXjTRW5ITVJ?
UACC-257 M4excGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrXfGFKSzVyPUSuN|k2OzRizszN NVjwcoFsW0GQR1XS
MC-CAR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRwNEO5PUDPxE1? MWDTRW5ITVJ?
COLO-320-HSR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3nTWM2OD12LkS0OFI4KM7:TR?= NH3XVVNUSU6JRWK=
P30-OHK Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT3TWM2OD12Lk[2OVgyKM7:TR?= MVjTRW5ITVJ?
UACC-812 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfrRXRSUUN3ME20MlY6OTZzIN88US=> M33ZU3NCVkeHUh?=
CTB-1 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwN{G1OVUh|ryP NITkeINUSU6JRWK=
ALL-PO NFTjTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGGwSnlKSzVyPUSuPFQxPzdizszN M4nqO3NCVkeHUh?=
SK-MEL-2 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD12Lki2PVU2KM7:TR?= MUTTRW5ITVJ?
TC-YIK M{Wxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwOUe5OFIh|ryP MoLDV2FPT0WU
NCI-H1882 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHDN|NxUUN3ME21MlAzODBzIN88US=> MmjqV2FPT0WU
MHH-CALL-2 M1[1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrGPZlIUUN3ME21MlA2ODR{IN88US=> MY\TRW5ITVJ?
U-87-MG MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHUclJCUUN3ME21MlA6PDZ4IN88US=> NH;4[29USU6JRWK=
NCI-H1092 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\VT2lEPTB;NT6yOlU2PSEQvF2= MnfxV2FPT0WU
TE-441-T M3vRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTVwMke4NkDPxE1? NGHKem9USU6JRWK=
SK-MEL-1 M1y0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTVwMkmwOFQh|ryP NHq5TFZUSU6JRWK=
EW-22 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXKTWM2OD13LkK5OFY3KM7:TR?= NUHESIVTW0GQR1XS
MZ7-mel MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn4VJNKSzVyPUWuOFA3QTFizszN M2LJR3NCVkeHUh?=
LP-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzJTWM2OD13LkSxNlkyKM7:TR?= MVTTRW5ITVJ?
NCI-SNU-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLLTWM2OD13Lk[0NFc1KM7:TR?= MXfTRW5ITVJ?
LU-65 NWPuZnExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nIOmlEPTB;NT63OlM4OyEQvF2= NVTEclgyW0GQR1XS
CW-2 NFn0bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XzOmlEPTB;NT64OVk2QSEQvF2= MX3TRW5ITVJ?
WSU-NHL MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS4SWZKSzVyPUWuPVUyPzRizszN M3;FVHNCVkeHUh?=
IST-MES1 M4P6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnId3VKSzVyPUWuPVU1PDNizszN MVfTRW5ITVJ?
U-266 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPwfJFGUUN3ME21Mlk5OjB{IN88US=> M3rpPHNCVkeHUh?=
TALL-1 NYnMT3lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTZwMUS2PFgh|ryP MojVV2FPT0WU
Calu-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTZwMUWzNVYh|ryP M{j1eXNCVkeHUh?=
MMAC-SF MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XZN2lEPTB;Nj6xPFU2PiEQvF2= M1zWPHNCVkeHUh?=
NCI-H82 NH;IN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrDfIFKSzVyPU[uNlA1QDlizszN MoPvV2FPT0WU
RS4-11 NVT5NItpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXMdIVKSzVyPU[uNlU5QTdizszN MlPCV2FPT0WU
SNU-C2B MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rsWmlEPTB;Nj60NFk3QSEQvF2= MknVV2FPT0WU
BOKU MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\BOZo4UUN3ME22MlQ4PTl5IN88US=> NYK4UmpyW0GQR1XS
C8166 Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\iZ|d6UUN3ME22MlU2QTF{IN88US=> NHXF[pVUSU6JRWK=
D-247MG Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\RU21oUUN3ME23MlA1OzR5IN88US=> NUS3Z2RCW0GQR1XS
EW-18 NWi3R5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LRXmlEPTB;Nz6wO|I6OiEQvF2= MWDTRW5ITVJ?
KG-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP6U|NuUUN3ME23MlYzPzN6IN88US=> NGC1ZXZUSU6JRWK=
REH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfabVFKSzVyPUeuOlgyODlizszN M2nvUHNCVkeHUh?=
U-698-M Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;VTWM2OD15Lki0N|E2KM7:TR?= M1KzdXNCVkeHUh?=
KP-N-RT-BM-1 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvsTWM2OD15LkmzNFI6KM7:TR?= M1nDU3NCVkeHUh?=
MS-1 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrXeVZKSzVyPUeuPVYxPDFizszN M2jrUnNCVkeHUh?=
SNU-C1 MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37yUGlEPTB;Nz65PFE6OiEQvF2= MkDwV2FPT0WU
SK-MM-2 M{DXcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW3WZdKSzVyPUiuNlYxPjVizszN M1vxTXNCVkeHUh?=
LAN-6 NIL2[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRThwM{CwNFEh|ryP MlHWV2FPT0WU
NEC8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRThwM{C2PVEh|ryP MoD5V2FPT0WU
NCI-H1770 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX0TWM2OD16LkO4NFAzKM7:TR?= NYi0OZB[W0GQR1XS
D-336MG NXrH[3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ZTY1CUUN3ME24MlQxOTF4IN88US=> MWTTRW5ITVJ?
COLO-829 NY[4eJJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK2UZFKSzVyPUiuOFg5PzlizszN MnTEV2FPT0WU
LS-513 NYPZUIR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRThwNUm1PVkh|ryP NFfuXFJUSU6JRWK=
YT MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L5bGlEPTB;OD62NlQzPyEQvF2= NIHrSHpUSU6JRWK=
EW-24 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG0TWM2OD16Lke2OVQh|ryP NHH1NG5USU6JRWK=
IST-SL1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwOE[1OFMh|ryP NVLlT5E6W0GQR1XS
CA46 M4fhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDORpFKSzVyPUiuPVUxQThizszN M3PlUnNCVkeHUh?=
NCI-H1838 M1jZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSxOGdRUUN3ME24Mlk5PjB{IN88US=> MlPpV2FPT0WU
NCI-H719 MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlwMkWyO|kh|ryP MnzKV2FPT0WU
HCE-T MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXWVXNKSzVyPUmuN|A5PTFizszN M3vrSXNCVkeHUh?=
A498 M37BVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;LPGlEPTB;OT6zOlEzPCEQvF2= M4PKOXNCVkeHUh?=
LB831-BLC M{LQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkmxTWM2OD17Lke2OVIyKM7:TR?= M{PHT3NCVkeHUh?=
SKM-1 NVi5c3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTlwOEW5OlMh|ryP NIDyXVNUSU6JRWK=
THP-1 NULGfo1GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWyTWM2OD17Lkm2PVE5KM7:TR?= MnzHV2FPT0WU
SHP-77 NWP2e2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHNbGhVUUN3ME2xNE41ODdizszN MULTRW5ITVJ?
EW-3 NX[0fpptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDBTmVKSzVyPUGwMlYzQDlizszN Mof4V2FPT0WU
KY821 NEC3enRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjN[G5KUUN3ME2xNE44PjNizszN NVzZN|NzW0GQR1XS
NCI-SNU-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITGTotKSzVyPUGxMlAzOTdizszN M3PDWXNCVkeHUh?=
HCC2218 NGL3W2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6ZVJ1UUN3ME2xNU4{QTh4IN88US=> MXjTRW5ITVJ?
IM-9 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHPTWM2OD1zMT61NVA3KM7:TR?= NVrsWVcxW0GQR1XS
NCI-H889 NFj2OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2wSFFxUUN3ME2xNU42OzF|IN88US=> M1T5WnNCVkeHUh?=
HDLM-2 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnIfXhqUUN3ME2xNk41OTV7IN88US=> Mkj3V2FPT0WU
LB2518-MEL MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\PUWlEPTB;MUKuOlgyPSEQvF2= MmnTV2FPT0WU
NCI-H23 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTWU3hbUUN3ME2xN{4zPDJ3IN88US=> M1z6OXNCVkeHUh?=
NB17 NYPoUopHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF|LkS1O|kh|ryP M4nZXXNCVkeHUh?=
NCI-H322M MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1zND60NFY5KM7:TR?= MWrTRW5ITVJ?
SUP-T1 NFTDNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rRcGlEPTB;MUSuOFE{KM7:TR?= M3nTNHNCVkeHUh?=
ES3 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X2PWlEPTB;MUWuNFcxOyEQvF2= MX;TRW5ITVJ?
ES5 Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF3LkC3PFch|ryP M17vSXNCVkeHUh?=
NCI-H1650 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1zNT60PVc6KM7:TR?= M2DnPXNCVkeHUh?=
NCI-H226 NHWwUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fiZWlEPTB;MUWuPFc3QCEQvF2= M1z3N3NCVkeHUh?=
COR-L88 NWTJOVJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrKTWM2OD1zNj6zNVQh|ryP NYG4XVhyW0GQR1XS
SCC-15 NEXRTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK0S|RvUUN3ME2xOk4{QDZ7IN88US=> Ml;6V2FPT0WU
GOTO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrRTWM2OD1zNj60O|k{KM7:TR?= NIOwfmtUSU6JRWK=
SIMA MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQUGlEPTB;MU[uOFgxOiEQvF2= MmfJV2FPT0WU
NCI-H1299 NVTxN3V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTY[nVFUUN3ME2xO{4yPTlzIN88US=> MmHiV2FPT0WU
NCI-H1581 NV31OHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXPS|UzUUN3ME2xO{41OjF7IN88US=> NW\2UYdlW0GQR1XS
MHH-NB-11 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv5SodFUUN3ME2xO{46Pjh|IN88US=> Ml;0V2FPT0WU
MFM-223 NWTjXnJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHftR3NKSzVyPUG4MlA2OzhizszN NFvEVpNUSU6JRWK=
ES7 M4i0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;CW5R2UUN3ME2xPE42PDNzIN88US=> MkP6V2FPT0WU
JVM-3 MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\EW3JpUUN3ME2xPE44OTdizszN NWLYVIRFW0GQR1XS
RL NWnLRo9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF34fYlKSzVyPUKwMlM5QCEQvF2= MUnTRW5ITVJ?
EC-GI-10 M4nIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJzLkKwOFEh|ryP Mm\HV2FPT0WU
LNCaP-Clone-FGC NFHOUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXKTWM2OD1{MT62O|Y5KM7:TR?= M{DURXNCVkeHUh?=
IMR-5 NET2PYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\uTWM2OD1{MT64OFk1KM7:TR?= NVXvWHpFW0GQR1XS
KP-N-YS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPwTWM2OD1{MT64O|Uh|ryP NHroOoZUSU6JRWK=
Mo-T MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfIb4Y3UUN3ME2yNk4zOTh3IN88US=> MkXOV2FPT0WU
NCI-H128 NF34OpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzTSYVFUUN3ME2yN{42QDV|IN88US=> Ml\HV2FPT0WU
RH-1 NH\sRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ|Lke4OlYh|ryP MlrxV2FPT0WU
NCI-H2171 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ2LkK0PFUh|ryP MXzTRW5ITVJ?
RPMI-8866 M2H1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHvTWM2OD1{Nj63OFIh|ryP MYDTRW5ITVJ?
SK-N-FI NF21[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDQTWM2OD1{Nz6zPFEyKM7:TR?= MnzzV2FPT0WU
LOXIMVI NUHvVG93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTxbphkUUN3ME2yO{45ODVzIN88US=> MnGxV2FPT0WU
P31-FUJ MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNzLkWzO|Qh|ryP M1Ha[HNCVkeHUh?=
KMS-12-PE NWPCTFQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljhTWM2OD12OT61N|AzKM7:TR?= M2rzRXNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
細胞試験:

[3]

+ 展開
  • 細胞株: U87-MG, T98G, and U373-MG
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • 製剤: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • 投薬量: ~4 mg/kg/day
  • 投与方法: Injection i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 914.18
化学式

C51H79NO13

CAS No. 53123-88-9
保管
別名 AY 22989,NSC-2260804

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

mTOR信号経路図

mTOR Inhibitors with Unique Features

相関mTOR製品

Tags: Rapamycin (Sirolimus)を買う | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus)供給者 | Rapamycin (Sirolimus)を購入する | Rapamycin (Sirolimus)費用 | Rapamycin (Sirolimus)生産者 | オーダーRapamycin (Sirolimus) | Rapamycin (Sirolimus)化学構造 | Rapamycin (Sirolimus)分子量 | Rapamycin (Sirolimus)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID